Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) concerning whether a series of statements by Alexion Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On November 9, 2016, Alexion Pharmaceuticals announced that its leading drug, Soliris, is being investigated for improper sales practices. Soliris is estimated to account for 92% of the Company's 2016 sales.  Alexion Pharmaceuticals retained outside counsel and revealed its decision to delay its third-quarter financial report.

Based in New Haven, Connecticut, and founded in 1992 Alexion Pharmaceuticals Inc develops and commercializes life-transforming therapeutic products.

If you purchased shares of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) on or before November 9, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185